Anti-vertigo drug prescribing for patients with vestibular symptoms in primary care: a retrospective observational cohort study
Rattachement africain : nl. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: There is limited evidence that anti-vertigo drugs (AVDs) are effective in patients with vestibular symptoms. Still, betahistine is one of the most frequently prescribed off-label drugs. GPs are likely to contribute substantially to these potentially inappropriate prescriptions. AIM: To evaluate the frequency of (long-term) AVD prescriptions in primary care and characteristics associated with long-term prescriptions. DESIGN & SETTING: We conducted a retrospective observational cohort study using anonymised routine primary care data from ≥1.2 million patients registered at 269 general practices throughout the Netherlands, covering the period 2018-2021. METHOD: We included adult patients with vestibular symptoms and/or AVD prescriptions. Outcomes were the prevalence and incidence of (long-term) AVD prescriptions. We used a multivariable logistic regression analysis to identify characteristics associated with long-term prescriptions. RESULTS: Among 66718 patients with vestibular symptoms, 6172 patients (9%) received AVD prescriptions of which 32% were long term. The majority of patients with prescriptions and long-term prescriptions (88% and 77%, respectively) had any other vestibular disorder than Ménière's disease. Still, Ménière's disease was associated with long-term prescriptions as well as increasing age. Patients with benign paroxysmal positional vertigo (BPPV) and a symptom diagnosis of lightheadedness were less likely to receive long-term prescriptions, in addition to patients registered at practices in extremely urbanised areas. CONCLUSION: AVD prescriptions, including long-term prescriptions, are common among patients with a wide array of vestibular symptoms and disorders, despite limited evidence. Management of vestibular symptoms by GPs can be improved by reducing these potentially inappropriate prescriptions.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Anti-vertigo drug prescribing for patients with vestibular symptoms in primary care: a retrospective observational cohort study
- Date Crossref
- 23/06/2025
- Éditeur
- Royal College of General Practitioners
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Amsterdam Neuroscience pays non établi dans la noticeStructure de recherche
-
Vrije Universiteit Amsterdam Amsterdam UMC pays non établi dans la noticeUniversité ou école supérieure
-
Amsterdam University Medical Centers pays non établi dans la noticeÉtablissement de santé
-
University Medical Center Groningen pays non établi dans la noticeÉtablissement de santé
-
University of Amsterdam pays non établi dans la noticeUniversité ou école supérieure
-
Amsterdam Public Health Research Institute pays non établi dans la noticeStructure de recherche
-
University Medical Centre Groningen pays non établi dans la noticeUniversité ou école supérieure
-
Amsterdam UMC pays non établi dans la noticeInstitution
Amsterdam Neuroscience, Amsterdam UMC — Vrije Universiteit Amsterdam et Amsterdam University Medical Centers, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.